睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07487519,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Archival FFPE tumor tissue (≤6 months old, ≤2 years max) for PD-L1 testing; fresh biopsy acceptable if archival tissue is unavailable or inadequate.

    入选标准第 7 条

  3. Phase II: Unresectable locally advanced, recurrent, or metastatic TNBC with no prior systemic anti-cancer therapy for this stage (palliative radiotherapy to metastases allowed; neoadjuvant/adjuvant therapy permitted if completed ≥6 months before recurrence/metastasis).

    入选标准第 5 条

    Second primary malignancy within 2 years before randomization (except cured carcinoma in situ or stage I tumors).

    排除标准第 2 条

  4. Phase I: Recurrent or metastatic TNBC after ≥1 prior line of standard systemic therapy.

    入选标准第 4 条

    Washout: ≥3 weeks (or 5 half-lives, whichever is shorter) after major surgery, radiotherapy (except palliative bone RT), chemotherapy, targeted therapy, or immunotherapy; ≥1 week after minor surgery or anti-tumor TCM. All treatment-related AEs resolved to CTCAE v6.0 Grade ≤1 (stable Grade 2 peripheral neuropathy and alopecia exempted).

    入选标准第 8 条

    Prior grade ≥3 immune-related adverse event during immunotherapy.

    排除标准第 3 条

  5. ECOG PS 0-1, assessed ≤7 days before randomization.

    入选标准第 9 条

  6. At least one RECIST v1.1-measurable lesion documented within 4 weeks before randomization.

    入选标准第 6 条

  7. Active HBV , HCV , or HBV/HCV co-infection.

    排除标准第 16 条

  8. Pregnancy or lactation.

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07487519,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary written informed consent obtained before any study procedures.
  2. Age ≥ 18 years at consent; no gender restriction.
  3. Histopathologically confirmed TNBC: ER < 1%, PR < 1%, HER2 IHC 0/1+/2+ with no FISH amplification.
  4. Phase I: Recurrent or metastatic TNBC after ≥1 prior line of standard systemic therapy.
  5. Phase II: Unresectable locally advanced, recurrent, or metastatic TNBC with no prior systemic anti-cancer therapy for this stage (palliative radiotherapy to metastases allowed; neoadjuvant/adjuvant therapy permitted if completed ≥6 months before recurrence/metastasis).
  6. At least one RECIST v1.1-measurable lesion documented within 4 weeks before randomization.
  7. Archival FFPE tumor tissue (≤6 months old, ≤2 years max) for PD-L1 testing; fresh biopsy acceptable if archival tissue is unavailable or inadequate.
  8. Washout: ≥3 weeks (or 5 half-lives, whichever is shorter) after major surgery, radiotherapy (except palliative bone RT), chemotherapy, targeted therapy, or immunotherapy; ≥1 week after minor surgery or anti-tumor TCM. All treatment-related AEs resolved to CTCAE v6.0 Grade ≤1 (stable Grade 2 peripheral neuropathy and alopecia exempted).
  9. ECOG PS 0-1, assessed ≤7 days before randomization.
  10. Life expectancy >3 months.
  11. Adequate hematologic, hepatic, and renal function per labs ≤7 days before randomization.

排除标准:Exclusion Criteria:

  1. Prior topoisomerase I-targeting therapy (e.g., irinotecan, topotecan, or ADCs).
  2. Second primary malignancy within 2 years before randomization (except cured carcinoma in situ or stage I tumors).
  3. Prior grade ≥3 immune-related adverse event during immunotherapy.
  4. Uncontrolled, recurrent malignant pleural, pericardial, or ascitic effusions requiring repeated drainage.
  5. Active CNS metastases, spinal cord compression, or carcinomatous meningitis.
  6. Clinically significant pulmonary impairment.
  7. Uncontrolled cardiovascular or cerebrovascular disease .
  8. Active systemic infection requiring IV antibiotics within 2 weeks before randomization.
  9. Moderate or strong CYP2D6/CYP3A inhibitor or inducer use within 2 weeks before randomization.
  10. Systemic corticosteroids (>10 mg/day prednisone equivalent) or other immunosuppressants within 2 weeks before randomization .
  11. Active or suspected autoimmune disease .
  12. Live or attenuated live vaccine within 4 weeks before randomization.
  13. Hypersensitivity to mAbs, large-molecule biologics, or drug formulation excipients.
  14. Active pulmonary tuberculosis.
  15. Known immunodeficiency.
  16. Active HBV , HCV , or HBV/HCV co-infection.
  17. Pregnancy or lactation.
  18. Participation in another interventional trial within 30 days before consent .
  19. Any condition posing unacceptable safety risk or interfering with study conduct per investigator judgment.

引自 ClinicalTrials.gov, NCT07487519, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07487519,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07487519